Xinjier (recombinant human interleukin-2 (125AIa) injection) / Peking University, Beijing SL Pharma - LARVOL DELTA

A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome (clinicaltrials.gov) - P2; N=60; Completed; Sponsor: Peking University People's Hospital; Recruiting ➔ Completed; Trial completion date: Dec 2016 ➔ Aug 2017; Trial primary completion date: Jun 2016 ➔ Mar 2017

Trial completion • Trial completion date • Trial primary completion date • Biosimilar • Immunology